Sunitinib effects on the radiation response of endothelial and breast tumor cells

Microvascular Research

Volumn 92, Issue , 2014, Pages 1-9

  El Kaffas, Ahmed ^a,b   Al Mahrouki, Azza ^a   Tran, William T ^a   Giles, Anoja ^a   Czarnota, Gregory J ^a,b  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR RECEPTOR; SUNITINIB; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL VIABILITY; CHEMORADIOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; ENDOTHELIUM CELL; FEMALE; IN VITRO STUDY; IN VIVO STUDY; IONIZING RADIATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIATION RESPONSE; RADIOGRAPHY DEVICE; ANIMAL; BREAST NEOPLASMS; CELL SURVIVAL; DRUG EFFECTS; DRUG SCREENING; HUMAN; MULTIMODALITY CANCER THERAPY; PATHOLOGY; SCID MOUSE; TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL;

MUS;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; COMBINED MODALITY THERAPY; ENDOTHELIAL CELLS; FEMALE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INDOLES; MICE; MICE, SCID; PYRROLES; RADIATION TOLERANCE; TUMOR STEM CELL ASSAY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84895927095     PISSN: 00262862     EISSN: 10959319     Source Type: Journal    
DOI: 10.1016/j.mvr.2013.10.008     Document Type: Article

References (77)

1. Abdollahi A., Folkman J. Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy. Drug Resist. Updat. 2010, 13:16-28.
2. Barcellos-Hoff M.H., Park C., Wright E.G. Radiation and the microenvironment - tumorigenesis and therapy. Nat. Rev. Cancer 2005, 5:867-875.
3. Bischof M., Abdollahi A., Gong P., Stoffregen C., Lipson K.E., Debus J.U., Weber K.J., Huber P.E. Triple combination of irradiation, chemotherapy (pemetrexed), and VEGFR inhibition (SU5416) in human endothelial and tumor cells. Int. J. Radiat. Oncol. Biol. Phys. 2004, 60:1220-1232.
4. Brooks C., Sheu T., Bridges K., Mason K., Kuban D., Mathew P., Meyn R. Preclinical evaluation of Sunitinib, a multi-tyrosine kinase inhibitor, as a radiosensitizer for human prostate cancer. Radiat. Oncol. 2012, 7:154.
5. Brown M., Bristow R., Glazer P., Hill R., McBride W., McKenna G., Muschel R. Comment on "tumor response to radiotherapy regulated by endothelial cell apoptosis" (II). Science 2003, 302:1894.
6. Cooney M.M., van Heeckeren W., Bhakta S., Ortiz J., Remick S.C. Drug insight: vascular disrupting agents and angiogenesis - novel approaches for drug delivery. Nat. Clin. Pract. Oncol. 2006, 3:682-692.
7. Cuneo K.C., Geng L., Fu A., Orton D., Hallahan D.E., Chakravarthy A.B. SU11248 (Sunitinib) sensitizes pancreatic cancer to the cytotoxic effects of ionizing radiation. Int. J. Radiat. Oncol. Biol. Phys. 2008, 71:873-879.
8. Czabanka M., Vinci M., Heppner F., Ullrich A., Vajkoczy P. Effects of Sunitinib on tumor hemodynamics and delivery of chemotherapy. Int. J. Cancer 2009, 124:1293-1300.
9. Ebos J.M.L., Lee C.R., Christensen J.G., Mutsaers A.J., Kerbel R.S. Multiple circulating proangiogenic factors induced by Sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:17069-17074.
10. Ebos J.M.L., Lee C.R., Cruz-Munoz W., Bjarnason G.A., Christensen J.G., Kerbel R.S. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009, 15:232-239.
11. El Kaffas A., Tran W., Czarnota G.J. Vascular strategies for enhancing tumour response to radiation therapy. TCRT 2012, 11:421-432.
12. El Kaffas A., Giles A., Czarnota G.J. Dose-dependent response of tumor vasculature to radiation therapy in combination with Sunitinib depicted by three-dimensional high-frequency power Doppler ultrasound. Angiogenesis 2013, 16:443-454.
13. Faivre S., Demetri G., Sargent W., Raymond E. Molecular basis for Sunitinib efficacy and future clinical development. Nat. Rev. Drug Discov. 2007, 6:734-745.
14. Fenton B.M., Lord E.M., Paoni S.F. Effects of radiation on tumor intravascular oxygenation, vascular configuration, development of hypoxia, and clonogenic survival. Radiat. Res. 2001, 155:360-368.
15. Fiebig H.H., Maier A., Burger A.M. Clonogenic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery. Eur. J. Cancer 2004, 40:802-820.
16. Folkman J., Camphausen K. What does radiotherapy do to endothelial cells?. Science 2001, 293:227.
17. Franses J.W., Edelman E.R. The evolution of endothelial regulatory paradigms in cancer biology and vascular repair. Cancer Res. 2011, 71:7339-7344.
18. Franses J.W., Baker A.B., Chitalia V.C., Edelman E.R. Stromal endothelial cells directly influence cancer progression. Sci. Transl. Med. 2011, 3:66ra5.
19. Fuks Z., Kolesnick R. Engaging the vascular component of the tumor response. Cancer Cell 2005, 8:89-91.
20. Fuks Z., Vlodavsky I., Andreeff M., McLoughlin M., Haimovitz-Friedman A. Effects of extracellular matrix on the response of endothelial cells to radiation in vitro. Eur. J. Cancer 1992, 28:725-731.
21. Fuks Z., Persaud R.S., Alfieri A., Mcloughlin M., Ehleiter D., Schwartz J.L., Seddon P., Cordon-cardo C. Basic fibroblast growth factor protects endothelial cells against radiation induced programmed cell death in vitro and in vivo. Cancer Res. 1994, 54:2582-2590.
22. Garcia-Barros M., Paris F., Cordon-Cardo C., Lyden D., Rafii S., Haimovitz-Friedman A., Fuks Z., Kolesnick R. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 2003, 300:1155-1159.
23. Garcia-Barros M., Lacorazza D., Petrie H., Haimovitz-Friedman A., Cardon-Cardo C., Nimer S., Fuks Z., Kolesnick R. Host acid sphingomyelinase regulates microvascular function not tumor immunity. Cancer Res. 2004, 64:8285-8291.
24. García-Barros M., Thin T.H., Maj J., Cordon-Cardo C., Haimovitz-Friedman A., Fuks Z., Kolesnick R. Impact of stromal sensitivity on radiation response of tumors implanted in SCID hosts revisited. Cancer Res. 2010, 70:8179-8186.
25. Gaustad J.-V., Simonsen T.G., Leinaas M.N., Rofstad E.K. Sunitinib treatment does not improve blood supply but induces hypoxia in human melanoma xenografts. BMC Cancer 2012, 12:388.
26. Gerweck L.E., Vijayappa S., Kurimasa A., Ogawa K., Chen D.J. Tumor cell radiosensitivity is a major determinant of tumor response to radiation. Cancer Res. 2006, 66:8352-8355.
27. Gordon M.S., Mendelson D.S., Kato G. Tumor angiogenesis and novel antiangiogenic strategies. Int. J. Cancer 2010, 126:1777-1787.
28. Griffioen A.W., Mans L.A., de Graaf A.M.A., Nowak-Sliwinska P., de Hoog C.L.M.M., de Jong T.A.M., Vyth-Dreese F.A., van Beijnum J.R., Bex A., Jonasch E. Rapid angiogenesis onset after discontinuation of Sunitinib treatment of renal cell carcinoma patients. Clin. Cancer Res. 2012, 18:3961-3971.
29. Gu Q., Wang D., Wang X., Peng R., Liu J., Jiang T., Wang Z., Wang S., Deng H. Basic fibroblast growth factor inhibits radiation-induced apoptosis of HUVECs. I. The PI3K/AKT pathway and induction of phosphorylation of BAD. Radiat. Res. 2004, 161:692-702.
30. Gupta N., Nodzenski E., Khodarev N.N., Yu J., Khorasani L., Beckett M.A., Kufe D.W., Weichselbaum R.R. Angiostatin effects on endothelial cells mediated by ceramide and RhoA. EMBO Rep. 2001, 2:536-540.
31. Haimovitz-Friedman A., Kan C.C., Ehleiter D., Persaud R.S., McLoughlin M., Fuks Z., Kolesnick R.N. Ionizing radiation acts on cellular membranes to generate ceramide and initiate apoptosis. J. Exp. Med. 1994, 180:525.
32. Herbst C., Kosmehl H., Stiller K.J., Berndt A., Eiselt M., Schubert J., Katenkamp D. Evaluation of microvessel density by computerised image analysis in human renal cell carcinoma. Correlation to pT category, nuclear grade, proliferative activity and occurrence of metastasis. J. Cancer Res. Clin. Oncol. 1998, 124:141-147.
33. Hillman G.G., Singh-Gupta V., Zhang H., Al-Bashir A.K., Katkuri Y., Li M., Yunker C.K., Patel A.D., Abrams J., Haacke E.M. Dynamic contrast-enhanced magnetic resonance imaging of vascular changes induced by Sunitinib in papillary renal cell carcinoma xenograft tumors. Neoplasia 2009, 11:910.
34. Hillman G.G., Singh-Gupta V., Al-Bashir A.K., Zhang H., Yunker C.K., Patel A.D., Sethi S., Abrams J., Haacke E.M. Dynamic contrast-enhanced magnetic resonance imaging of Sunitinib-induced vascular changes to schedule chemotherapy in renal cell carcinoma xenograft. Transl. Oncol. 2010, 3:293-306.
35. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62.
36. Kamrava M., Bernstein M.B., Camphausen K., Hodge J.W. Combining radiation, immunotherapy, and antiangiogenesis agents in the management of cancer: the three musketeers or just another quixotic combination?. Mol. Biosyst. 2009, 5:1262-1270.
37. Kleibeuker E.A., Griffioen A.W., Verheul H.M., Slotman B.J., Thijssen V.L. Combining angiogenesis inhibition and radiotherapy: a double-edged sword. Drug Resist. Updat. 2012, 15:173-182.
38. Kolesnick R. Response to comments on "tumor response to radiotherapy regulated by endothelial cell apoptosis". Science 2003, 302:1894e.
39. Kolesnick R., Fuks Z. Radiation and ceramide-induced apoptosis. Oncogene 2003, 22:5897-5906.
40. Korah R.M., Sysounthone V., Golowa Y., Wieder R. Basic fibroblast growth factor confers a less malignant phenotype in MDA-MB-231 human breast cancer cells. Cancer Res. 2000, 60:733.
41. Kozin S.V., Boucher Y., Hicklin D.J., Control R.L., Tumor H., Bohlen P., Jain R.K., Suit H.D. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res. 2001, 61:39-44.
42. Li J., Huang S., Armstrong E.A., Fowler J.F., Harari P.M. Angiogenesis and radiation response modulation after vascular endothelial growth factor receptor-2 (VEGFR2) blockade. Int. J. Radiat. Oncol. Biol. Phys. 2005, 62:1477-1485.
43. Maggiorella L., Aubel C., Haton C., Milliat F., Connault E., Opolon P., Deutsch E., Bourhis J. Cooperative effect of roscovitine and irradiation targets angiogenesis and induces vascular destabilization in human breast carcinoma. Cell Prolif. 2009, 42:38-48.
44. Maj J.G., Paris F., Haimovitz-friedman A. Microvascular function regulates intestinal crypt response to radiation microvascular function regulates intestinal crypt response to radiation. Cancer Res. 2003, 4338-4341.
45. McGee M.C., Hamner J.B., Williams R.F., Rosati S.F., Sims T.L., Ng C.Y., Gaber M.W., Calabrese C., Wu J., Nathwani A.C., Duntsch C., Merchant T.E., Davidoff A.M. Improved intratumoral oxygenation through vascular normalization increases glioma sensitivity to ionizing radiation. Int. J. Radiat. Oncol. Biol. Phys. 2010, 76:1537-1545.
46. Mendel D.B., Laird A.D., Xin X., Louie S.G., Christensen J.G., Li G., Schreck R.E., Abrams T.J., Ngai T.J., Lee L.B., Murray L.J., Carver J., Chan E., Moss K.G., Haznedar J.O., Sukbuntherng J., Blake R.A., Sun L., Tang C., Miller T., Shirazian S., McMahon G., Cherrington J.M. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 2003, 9:327-337.
47. Moeller B.J., Cao Y., Li C.Y., Dewhirst M.W. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 2004, 5:429-441.
48. Nakatsu M.N., Sainson R.C.A., Aoto J.N., Taylor K.L., Aitkenhead M., Carpenter P.M., Hughes C.C.W. Angiogenic sprouting and capillary lumen formation modeled by human umbilical vein endothelial cells (HUVEC) in fibrin gels: the role of fibroblasts and Angiopoietin-1. Microvasc. Res. 2003, 66:102-112.
49. O'Reilly M.S. Radiation combined with antiangiogenic and antivascular agents. Semin. Radiat. Oncol. 2006, 16:45-50.
50. Ogawa K., Boucher Y., Kashiwagi S., Fukumura D., Chen D., Gerweck L.E. Influence of tumor cell and stroma sensitivity on tumor response to radiation. Cancer Res. 2007, 67:4016-4021.
51. Osusky K.L., Hallahan D.E., Fu A., Ye F., Shyr Y., Geng L. The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels. Angiogenesis 2004, 7:225-233.
52. Paris F., Fuks Z., Kang A., Capodieci P., Juan G., Ehleiter D., Haimovitz-Friedman A., Cordon-Cardo C., Kolesnick R. Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science 2001, 293:293.
53. Park H.J., Griffin R.J., Hui S., Levitt H., Song C.W. Radiation-induced vascular damage in tumors: implications of vascular damage in ablative hypofractionated radiotherapy (SBRT and SRS). Vascular 2012, 327:311-327.
54. Peña L.A., Fuks Z., Kolesnick R.N. Radiation-induced apoptosis of endothelial cells in the murine central nervous system: protection by fibroblast growth factor and sphingomyelinase deficiency. Cancer Res. 2000, 60:321-327.
55. Prise K.M., Schettino G., Folkard M., Held K.D. New insights on cell death from radiation exposure. Lancet Oncol. 2005, 6:520-528.
56. Rotolo J.A., Kolesnick R., Fuks Z. Timing of lethality from gastrointestinal syndrome in mice revisited. Int. J. Radiat. Oncol. Biol. Phys. 2009, 73:6-8.
57. Ruka W., Taghian A., Gioioso D., Fletcher J.A., Preffer F., Suit H.D. Comparison between the in vitro intrinsic radiation sensitivity of human soft tissue sarcoma and breast cancer cell lines. J. Surg. Oncol. 1996, 61:290-294.
58. Sabo E., Boltenko A., Sova Y. Microscopic analysis and significance of vascular architectural complexity in renal cell carcinoma. Clin. Cancer Res. 2001, 7:533-537.
59. Schueneman A.J., Himmelfarb E., Geng L., Tan J., Donnelly E., Mendel D., McMahon G., Hallahan D.E. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res. 2003, 63:4009-4016.
60. Schwartz D.L., Bankson J.A., Bidaut L., He Y., Williams R.R., Lemos R., Thittai A.K., Oh J., Volgin A.Y., Soghomonyan S., Yeh H.-H., Nishii R., Mukhopadhay U., Alauddin M., Mushkudiani I., Kuno N., Krishnan S., Bornman W., Lai S.Y., Powis G., Hazle J.D., Gelovani J.G. HIF-1 dependent stromal adaptation to ischemia mediates in vivo tumor radiation resistance. Mol. Cancer Res. 2011, 9:259-270.
61. Senan S., Smit E.F. Design of clinical trials of radiation combined with antiangiogenic therapy. Oncologist 2007, 12:465-477.
62. Suarez C., Rini B.I. Determining the optimal dose and schedule of Sunitinib: some answers, more questions. Cancer 2012, 118:1178-1180.
63. Suit H.D., Willers H. Comment on "tumor response to radiotherapy regulated by endothelial cell apoptosis" (I). Science 2003, 302:1894.
64. Sun J., Sun Q., Brown M.F., Dudgeon C., Chandler J., Xu X., Shu Y., Zhang L., Yu J. The multi-targeted kinase inhibitor Sunitinib induces apoptosis in colon cancer cells via puma. PLoS One 2012, 7:e43158.
65. Timke C., Zieher H., Roth A., Hauser K., Lipson K.E., Weber K.J., Debus J., Abdollahi A., Huber P.E. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy. Clin. Cancer Res. 2008, 14:2210-2219.
66. Tran T.C., Sneed B., Haider J., Tran T.C., Sneed B., Haider J., Blavo D., White A., Aiyejorun T., Baranowski T.C., Rubinstein A.L. Automated, quantitative screening assay for antiangiogenic compounds using transgenic zebrafish. Cancer Res. 2007, 67:11386-11392.
67. Truman J., Hambardzumyan D., Garcia-Barros M., Chan R., Fuks Z., Haimovitz-Friedman A. Basic fibroblast growth factor inhibits radiation-induced apoptosis of endothelial cells by inhibiting acid sphingomyelinase activity. Radiother. Oncol. 2006, 78:S74.
68. Truman J.-P., García-Barros M., Kaag M., Hambardzumyan D., Stancevic B., Chan M., Fuks Z., Kolesnick R., Haimovitz-Friedman A. Endothelial membrane remodeling is obligate for anti-angiogenic radiosensitization during tumor radiosurgery. PLoS One 2010, 5:e12310.
69. Vit J.-P., Rosselli F. Role of the ceramide-signaling pathways in ionizing radiation-induced apoptosis. Oncogene 2003, 22:8645-8652.
70. Wachsberger P., Burd R., Dicker A.P. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. Clin. Cancer Res. 2003, 9:1957-1971.
71. Winkler F., Kozin S.V., Tong R.T., Chae S.-S., Booth M.F., Garkavtsev I., Xu L., Hicklin D.J., Fukumura D., di Tomaso E., Munn L.L., Jain R.K. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004, 6:553-563.
72. Yoon S.S., Stangenberg L., Lee Y.-J., Rothrock C., Dreyfuss J.M., Baek K.-H., Waterman P.R., Nielsen G.P., Weissleder R., Mahmood U., Park P.J., Jacks T., Dodd R.D., Fisher C.J., Ryeom S., Kirsch D.G. Efficacy of Sunitinib and radiotherapy in genetically engineered mouse model of soft-tissue sarcoma. Int. J. Radiat. Oncol. Biol. Phys. 2009, 74:1207-1216.
73. Yoon C.Y., Lee J.S., Kim B.S., Jeong S.J., Hong S.K., Byun S.S., Lee S.E. Sunitinib malate synergistically potentiates anti-tumor effect of gemcitabine in human bladder cancer cells. Korean J. Urol. 2011, 52:55-63.
74. Zhang H.-P., Takayama K., Su B., Jiao X., Li R., Wang J.-J. Effect of Sunitinib combined with ionizing radiation on endothelial cells. J. Radiat. Res. 2011, 52:1-8.
75. Zhou Q., Gallo J.M. Differential effect of Sunitinib on the distribution of temozolomide in an orthotopic glioma model. Neuro Oncol. 2009, 11:301-310.
76. Zhou Q., Gallo J.M. Quantification of Sunitinib in mouse plasma, brain tumor and normal brain using liquid chromatography-electrospray ionization-tandem mass spectrometry and pharmacokinetic application. J. Pharm. Biomed. Anal. 2010, 51:958-964.
77. Zwolak P., Jasinski P., Terai K., Gallus N.J., Ericson M.E., Clohisy D.R., Dudek A.Z. Addition of receptor tyrosine kinase inhibitor to radiation increases tumour control in an orthotopic murine model of breast cancer metastasis in bone. Eur. J. Cancer 2008, 44:2506-2517.